IMMU

Submission status for IMMUNOMEDICS INC's drug TRODELVY (SUPPL-63) with active ingredient SACITUZUMAB GOVITECAN-HZIY has changed to 'Approval' on 06/24/2026. Application Category: BLA, Application Number: 761115, Application Classification:

Submission status for IMMUNOMEDICS INC's drug TRODELVY (SUPPL-64) with active ingredient SACITUZUMAB GOVITECAN-HZIY has changed to 'Approval' on 06/24/2026. Application Category: BLA, Application Number: 761115, Application Classification:

Submission status for IMMUNOMEDICS INC's drug TRODELVY (SUPPL-58) with active ingredient SACITUZUMAB GOVITECAN-HZIY has changed to 'Approval' on 11/22/2024. Application Category: BLA, Application Number: 761115, Application Classification:

NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Peter (Pete) Pfreundschuh to its Board of Managers, effective April 1, 2024. Following this appointment, the Board will comprise of 9 directors, 6 of whom are non-executive. "We are pleased to welcome Pete to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Pete has deep experience in the pharmaceutical and biotechnology industry, with extensive knowledge in corporate finance, business

Submission status for IMMUNOMEDICS INC's drug TRODELVY (SUPPL-35) with active ingredient SACITUZUMAB GOVITECAN-HZIY has changed to 'Approval' on 02/03/2023. Application Category: BLA, Application Number: 761115, Application Classification:

Submission status for IMMUNOMEDICS INC's drug TRODELVY (SUPPL-23) with active ingredient SACITUZUMAB GOVITECAN-HZIY has changed to 'Approval' on 06/03/2022. Application Category: BLA, Application Number: 761115, Application Classification:

Submission status for IMMUNOMEDICS INC's drug TRODELVY (SUPPL-9) with active ingredient SACITUZUMAB GOVITECAN-HZIY has changed to 'Approval' on 04/13/2021. Application Category: BLA, Application Number: 761115, Application Classification:

Submission status for IMMUNOMEDICS INC's drug TRODELVY (SUPPL-13) with active ingredient SACITUZUMAB GOVITECAN-HZIY has changed to 'Approval' on 04/07/2021. Application Category: BLA, Application Number: 761115, Application Classification:

Submission status for IMMUNOMEDICS INC's drug TRODELVY (SUPPL-5) with active ingredient SACITUZUMAB GOVITECAN-HZIY has changed to 'Approval' on 04/07/2021. Application Category: BLA, Application Number: 761115, Application Classification:

SC 13G/A - IMMUNOMEDICS INC (0000722830) (Subject)

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that it has named Peter P. Pfreundschuh as its new chief financial officer. Mr. Pfreundschuh will oversee the Company’s financial strategy and activities related to accounting, investor relations, business development and business operations. Mr. Pfreundschuh joins Frequency from UroGen Pharma Ltd., a commercial-stage biopharma company, where he served as chief financial officer, chief compliance officer and corporate secretary.

HANOVER, MD, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high unmet medical need, is pleased to announce the appointment of Dr. Khalid Islam to its board of directors. “I’d like to personally welcome Dr. Islam to the board,” commented Dr. David Young, Chairman and CEO of Processa Pharmaceuticals. “Dr. Islam’s extensive experience and insight within the pharmaceutical industry and his diverse perspectives will be a great addition to the board and the Company.” Dr. Islam was the chairman and

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire Immunomedics, Inc. (Nasdaq: IMMU) for approximately $21 billion in the aggregate. “We are very pleased to reach today’s milestone and to welcome the talented Immunomedics team to the Gilead family. There is a lot of important work ahead of us to deliver on the vast potential that Trodelvy offers for patients with cancer,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences. “Together we will bring Trodelvy to many more patients around the world with triple-negative breast cancer and continue to explore its

LEIDEN, Netherlands, Oct. 20, 2020 /PRNewswire/ -- ProteoNic BV, a leading provider of technology and services in the field of production of biologics, today announced it has licensed its premium 2G UNic™ technology for boosting therapeutic protein production to Immunomedics, Inc. (NASDAQ: IMMU), a biopharmaceutical company developing immuno-therapeutics for the treatment of cancer and other diseases. Under the agreement, Immunomedics gains commercial rights for application of ProteoNic's technology platform to the development of specified proprietary products from mammalian cells. Financial details of the agreement were not disclosed. ProteoNic's protein expression technology improves p

NEW YORK, Oct. 5, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating: Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to a consortium that includes members of Cellular Biomedicine management and several entities. Visit our website to learn more about your legal rights and options: https://halpersadeh.com/actions/cellular-biomedicine-group-inc-cbmg-stock-merger/. Virtusa Corporation (NASDAQ: VRTU) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to funds affilia

NEW YORK, Oct. 2, 2020 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq.WeissLaw LLP1500 Broadway, 16th FloorNew York, NY  10036(212) 682-3025(888) 593-4771[email protected] Montage Resources Corporation (NYSE: MR) WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Montage Resources Corporation (NYSE: MR) in connection with the proposed acquisition of the company by Southwestern Energy Company ("SWN").  Under the terms of the agreement, MR share

NEW YORK, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.   Moore Kuehn may ultimately seek increased consideration, additional disclosures, or other relief and benefits on behalf of the shareholders of these companies: Immunomedics, Inc. (NASDAQ: IMMU) A solicitation statement was recently filed with the SEC regarding Gilead Sciences’ acquisition of Immunomedics, which may omit material information regarding the financial metrics and analyses used to evaluate the merger.   Under the propo

NEW YORK, Sept. 25, 2020 /PRNewswire/ -- Montage Resources Corporation WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Montage Resources Corporation in connection with the proposed acquisition of the company by Southwestern Energy Company ("SWN").  Under the terms of the agreement, MR shareholders will receive 1.8656 shares of SWN for each share of MR common stock they own, representing implied per-share consideration of approximately $4.76 based upon SWN's September 24, 2020 closing price of $2.55.  If you own MR shares and wish to discuss this investigation or your rights, please call us at one of the numbers lis

NEW YORK, Sept. 25, 2020 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq.WeissLaw LLP1500 Broadway, 16th FloorNew York, NY  10036(212) 682-3025(888) 593-4771[email protected] Akcea Therapeutics, Inc. (NASDAQ: AKCA) WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Akcea Therapeutics, Inc. (NASDAQ: AKCA) in connection with the proposed acquisition of the company by Ionis Pharmaceuticals, Inc. ("IONS").  Under the terms of the acquisition agreeme

SAN DIEGO, Sept. 20, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Immunomedics Inc. (NASDAQ: IMMU) ("Immunomedics" or the "Company") breached their fiduciary duties in connection with the proposed sale of the Company to Gilead Sciences, Inc.   On September 13, 2020, Immunomedics announced that it had entered into a definitive merger agreement with Gilead. Under the terms of the acquisition agreement, the Company's shareholders will receive $88 per share in cash. The investigation concerns whether the Immunomedics board failed to satisfy its duties to the Company shareholders, including whether the boar

Trodelvy achieves a 27 percent overall response rate and a 5.9-month median duration of response in heavily-pretreated patients with metastatic urothelial cancer (mUC) sBLA submission for accelerated approval expected in fourth quarter 2020, pending FDA final guidance Phase 3 TROPiCS-04 study in third-line mUC underway Company to host conference call and webcast today at 2:00 p.m. Eastern Time MORRIS PLAINS, N.J., Sept. 19, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced positive results from cohort 1 of cisplatin-eligible patients in the pivotal Ph

Trodelvy significantly reduced the risk of death by 52 percent, with a median overall survival (OS) of 12.1 months compared to 6.7 months for standard single-agent chemotherapy Trodelvy is the first ADC to significantly improve OS in metastatic triple-negative breast cancer (mTNBC) sBLA for full approval to be submitted in fourth quarter 2020 under RTOR process Company to host conference call and webcast today at 2:00 p.m. Eastern Time MORRIS PLAINS, N.J., Sept. 19, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that results from the confir

NEW YORK, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of Immunomedics to Gilead Sciences, Inc. for $88.00 per share in cash. If you are a IMMU investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com. Livongo Health, Inc. (NASDAQ:LVGO) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of LVGO to Teladoc Health, Inc. for 0.59

PLAM BEACH, Fla., Sept. 16, 2020 /PRNewswire/ -- The National Institute for Health (NIH) is at the heart of the emerging and rapidly evolving war against the global pandemic. They constantly update the public on the latest information on research for a vaccine and therapies to fight the virus. A recent report from them shone the light on a specific promising therapeutic approach… nanomedicine. The NIH said that nanomedicine is a promising approach for diagnosis, treatment and prophylaxis against COVID-19. They said that: "The COVID-19 pandemic caused by the newly emerged severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) puts the world in an unprecedented crisis, leaving behind

NEW YORK, Sept. 15, 2020 /PRNewswire/ -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.  Moore Kuehn may ultimately seek increased consideration, additional disclosures, or other relief and benefits on behalf of the shareholders of these companies: Immunomedics, Inc. (NASDAQ: IMMU) Immunomedics has agreed to be acquired by Gilead Sciences.  Under the proposed transaction, shareholders of Immunomedics will receive $88.00 in cash for every share owned. On Deck Capital, Inc. (NYSE: ONDK) A registration statement was recently